about
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainIS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVETreating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixiValue For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In ItalyNasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact AnalysisCost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes
P50
description
researcher
@en
wetenschapper
@nl
name
Johannes Pöhlmann
@en
Johannes Pöhlmann
@nl
type
label
Johannes Pöhlmann
@en
Johannes Pöhlmann
@nl
prefLabel
Johannes Pöhlmann
@en
Johannes Pöhlmann
@nl
P31
P496
0000-0002-8065-755X